Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Agios Pharmaceuticals (NASDAQ:AGIO) and lowers the price target from $32 to $28.

November 03, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a Neutral rating on Agios Pharmaceuticals and lowered the price target from $32 to $28.
The news directly pertains to Agios Pharmaceuticals as Goldman Sachs has maintained a Neutral rating on the company and lowered the price target. This could potentially influence investor sentiment and impact the stock's price, although the Neutral rating suggests that the impact may not be significant in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100